Latest News

Cardinal Health could raise prices to offset tariffs

Cardinal Health could raise prices to offset tariffs

Cardinal Health, a drug distributor, said that it could be forced to raise prices on some of its products in order to offset the rising costs of manufacturing within the region if proposed tariffs against Mexico are implemented.

In an interview, CEO Jason Hollar said that it is difficult to redirect production away from Mexico because the costs of production are "pretty cheap".

Mexico, together with China and Canada has been

threatened

Donald Trump has imposed tariffs on U.S. goods

The countries cannot be a threat to each other

Stop the flow of illegal immigrants into the U.S. and stop the dangerous opioid fentanyl.

Hollar said that if there is a widespread increase in tariffs from 10% to 25%, the price will rise for customers.

Cardinal has said that it may move its production from China to Southeast Asia, where it is expected to be affected both by tariffs and the limited exposure to supply chains.

The company stated that it closely monitored the "highly volatile tariff environment", but did not indicate if potential tariff effects had been factored in to its fiscal 2025 outlook.

Cardinal, a Dublin, Ohio, based company, said earlier in the day that it was expecting an adjusted profit between $7.85 and $8.00 per share. It attributed this to the strong demand of expensive specialty drugs and branded medications in its Pharmaceuticals Unit.

Cardinal had forecasted a profit between $7.75 and $7.90 for the fiscal year 2025, which ends on June 30. LSEG data shows that analysts were expecting a profit per share of $7.86.

According to LSEG, Cardinal Health's adjusted profit per share was $1.93, which beat analysts' expectations of $1.76, according to LSEG. (Reporting from Kamal Choudhury in Bengaluru and Christy Santhosh; editing by Tasim Zaid)

(source: Reuters)